🛡️ Immunology: Historical Timeline & Scientific Milestones

Demonstrated that inoculation with mild cowpox matter protected against subsequent infection by virulent smallpox, establishing the paradigm of immunization.

Inserted rose thorns into transparent starfish larvae and observed mobile amoeboid mesodermal cells engulfing and destroying foreign invaders, discovering phagocytosis (1908 Nobel Prize).

Injected animals with sublethal doses of diphtheria toxin and showed that cell-free blood serum contained neutralizing antitoxins capable of passive curative transfer (1901 First Nobel Prize in Medicine).

Demonstrated that bacteriolysis requires two factors: a heat-stable specific antibody and a heat-labile non-specific serum component he called 'alexin', later renamed 'complement' (1919 Nobel Prize).

Proposed that cells possess specific surface side-chains (receptors) that fit toxins like lock-and-key; toxin binding stimulates the cell to overproduce and shed these receptors into the bloodstream as antibodies (1908 Nobel Prize).

Mixed erythrocytes and sera from laboratory colleagues, discovering that sera agglutinated red cells of some individuals but not others, identifying blood groups A, B, and O (1930 Nobel Prize).

Attempted to immunize dogs with sublethal jellyfish tentacle toxin; a tiny booster dose weeks later caused fatal cardiovascular collapse within minutes, coining 'anaphylaxis' ('anti-protection') (1913 Nobel Prize).

Immunized rabbits with Rhesus monkey red blood cells and found the antibodies agglutinated 85% of human red cells (Rh-positive), explaining erythroblastosis fetalis in Rh-negative mothers carrying Rh-positive fetuses.

Injected allogeneic fetal or neonatal mice with donor bone marrow cells and proved that upon adulthood, these mice accepted skin allografts from the marrow donor without graft rejection (1960 Nobel Prize).

Discovered that chickens surgically bursectomized as hatchlings failed to produce antibodies upon Salmonella vaccination, while cell-mediated graft rejection remained intact, bifurcating B cells and T cells.

Proposed that antigen does not serve as an instructive template for antibody folding, but selectively binds to pre-existing, genetically committed lymphocytes carrying matching surface receptors, stimulating their clonal expansion (1960 Nobel Prize).

Porter used papain digestion to cleave IgG into two Fab (antigen-binding) fragments and one Fc (crystallizable) fragment; Edelman reduced disulfide bonds to isolate two heavy (H) and two light (L) chains (1972 Nobel Prize).

Surgically removed the thymus from newborn mice, demonstrating severe lymphopenia, wasting syndrome, inability to reject foreign skin grafts, and complete loss of cell-mediated immunity.

Classified harmful immune-mediated tissue injury into four distinct mechanistic categories: Type I (Immediate), Type II (Cytotoxic), Type III (Immune Complex), and Type IV (Delayed-Type Cellular).

Purified reaginic serum antibodies from allergic patients, proving it was a distinct fifth immunoglobulin class (IgE) present in trace concentrations with profound mast-cell-sensitizing properties.

Showed that cytotoxic T lymphocytes from mice infected with lymphocytic choriomeningitis virus (LCMV) could only lyse target cells that both expressed viral antigens AND shared the identical Major Histocompatibility Complex (MHC) haplotype (1996 Nobel Prize).

Fused short-lived normal antibody-producing spleen B cells with immortal HGPRT-deficient myeloma cells using polyethylene glycol (PEG), generating hybridomas that secrete unlimited identical monoclonal antibodies (1984 Nobel Prize).

Compared restriction endonuclease fragments of immunoglobulin genes in embryonic tissue versus mature antibody-secreting myeloma cells, proving that separate V, D, and J germline gene segments physically rearrange during lymphocyte development (1987 Nobel Prize).

Simultaneously cloned the beta-chain cDNA of the human and murine T-cell receptor using subtractive hybridization, demonstrating that the TCR is a heterodimer structurally homologous to immunoglobulins that undergoes somatic V(D)J rearrangement.

Cloned mouse CD4+ T helper cell lines, discovering two functionally mutually inhibitory subsets based on cytokine secretion: Th1 (IFN-gamma, IL-2) promoting cell-mediated immunity, and Th2 (IL-4, IL-5, IL-13) driving humoral allergy.

Solved the first 3.5-Angstrom crystal structure of a human Major Histocompatibility Complex molecule (HLA-A2), revealing a deep peptide-binding cleft formed by two antiparallel alpha-helices atop an eight-stranded beta-pleated sheet.

Demonstrated that depleting CD4+CD25+ T cells from normal mice provoked fatal multi-organ autoimmune disease, proving a dedicated suppressor subset of T lymphocytes actively preserves peripheral self-tolerance.

Medzhitov and Janeway identified the human homolog of Drosophila Toll (hToll/TLR4); Beutler positional-cloned the Lps gene mutation in C3H/HeJ mice, proving TLR4 is the essential membrane sensor for Gram-negative bacterial lipopolysaccharide (LPS).

Awarded the 2011 Nobel Prize in Physiology or Medicine: Steinman for discovering dendritic cells (DCs) as master professional antigen-presenting cells bridging innate and adaptive immunity; Hoffmann and Beutler for Toll/TLR innate sensing.

Achieved complete, durable remissions in relapsed pediatric B-cell acute lymphoblastic leukemia (ALL) by genetically engineering patient T cells with a synthetic Chimeric Antigen Receptor (CAR) directed against CD19 (Kymriah).

Allison showed that blocking CTLA-4 with monoclonal antibodies unleashes cytotoxic T-cell tumor eradication; Honjo identified PD-1 as an inhibitory receptor on exhausted T cells (2018 Nobel Prize).

Engineered dual-specificity artificial recombinant antibodies that simultaneously bind a tumor surface antigen (e.g. CD19, BCMA) with one arm and CD3 on polyclonal T cells with the other arm, forcing immune synapse formation.

Discovered that replacing uridine with N1-methylpseudouridine prevents exogenous synthetic mRNA from triggering inflammatory toll-like receptors (TLR7/TLR8), enabling high-level translation of viral antigen proteins in vivo (2023 Nobel Prize).